- Home
- NBIX vs FMS Comparison
NBIX vs FMS Comparison
Compare NBIX & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- FMS
- Stock Information
- Founded
- NBIX 1992
- FMS 1996
- Country
- NBIX United States
- FMS Germany
- Employees
- NBIX N/A
- FMS N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- FMS Misc Health and Biotechnology Services
- Sector
- NBIX Health Care
- FMS Health Care
- Exchange
- NBIX Nasdaq
- FMS Nasdaq
- Market Cap
- NBIX 13.1B
- FMS 14.1B
- IPO Year
- NBIX 1996
- FMS 1996
- Fundamental
- Price
- NBIX $135.45
- FMS $23.02
- Analyst Decision
- NBIX Buy
- FMS Hold
- Analyst Count
- NBIX 23
- FMS 1
- Target Price
- NBIX $165.00
- FMS $23.00
- AVG Volume (30 Days)
- NBIX 910.2K
- FMS 214.6K
- Earning Date
- NBIX 02-05-2025
- FMS 11-05-2024
- Dividend Yield
- NBIX N/A
- FMS 2.69%
- EPS Growth
- NBIX 97.40
- FMS 46.47
- EPS
- NBIX 3.73
- FMS 2.50
- Revenue
- NBIX $2,242,800,000.00
- FMS $21,457,738,113.00
- Revenue This Year
- NBIX $27.07
- FMS $0.24
- Revenue Next Year
- NBIX $16.60
- FMS $3.41
- P/E Ratio
- NBIX $36.12
- FMS $19.12
- Revenue Growth
- NBIX 25.72
- FMS N/A
- 52 Week Low
- NBIX $110.95
- FMS $17.93
- 52 Week High
- NBIX $157.98
- FMS $24.31
- Technical
- Relative Strength Index (RSI)
- NBIX 68.12
- FMS 52.85
- Support Level
- NBIX $125.61
- FMS $23.58
- Resistance Level
- NBIX $130.48
- FMS $24.07
- Average True Range (ATR)
- NBIX 2.92
- FMS 0.31
- MACD
- NBIX 0.72
- FMS -0.09
- Stochastic Oscillator
- NBIX 69.33
- FMS 47.98
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
About FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating over 300,000 patients from roughly 3,750 clinics across the globe as of mid-2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%.